BACKGROUND: Vitamin D deficiency is highly prevalent among hemodialysis patients, but little data exist in support of an optimal repletion regimen. OBJECTIVE: The objective was to ascertain the efficacy of weekly very-high-dose cholecalciferol (vitamin D(3)) in correcting vitamin D insufficiency and deficiency in patients with stage 5D chronic kidney disease. DESIGN: We conducted a prospective, double-blind, randomized controlled pilot study that compared placebo with very high doses of oral cholecalciferol for 3 wk (200,000 IU/wk) in hemodialysis patients. We examined the rate of correction of vitamin D insufficiency or deficiency and the effect of treatment on markers of mineral metabolism and routine laboratory variables. RESULTS: Twenty-seven subjects received placebo, and 25 received cholecalciferol. The majority (94%) of subjects had serum 25-hydroxyvitamin D [25(OH)D] concentrations <30 ng/mL. Study groups were similar with respect to baseline clinical characteristics, with the exception of hemoglobin concentrations, which were lower in the cholecalciferol-treated group (P < 0.04). At follow-up, 90.5% of subjects treated with cholecalciferol achieved serum 25(OH)D concentrations≥30 ng/mL in contrast to 13.6% of the placebo group. There were no significant changes in serum calcium, phosphate, or intact parathyroid hormone during the study. CONCLUSION: Short-term, high-dose oral cholecalciferol treatment of vitamin D deficiency in hemodialysis patients appears to be effective and with no evidence of toxic effects. This trial was registered at clinicaltrials.gov as NCT00912782.
RCT Entities:
BACKGROUND:Vitamin D deficiency is highly prevalent among hemodialysis patients, but little data exist in support of an optimal repletion regimen. OBJECTIVE: The objective was to ascertain the efficacy of weekly very-high-dose cholecalciferol (vitamin D(3)) in correcting vitamin Dinsufficiency and deficiency in patients with stage 5D chronic kidney disease. DESIGN: We conducted a prospective, double-blind, randomized controlled pilot study that compared placebo with very high doses of oral cholecalciferol for 3 wk (200,000 IU/wk) in hemodialysis patients. We examined the rate of correction of vitamin Dinsufficiency or deficiency and the effect of treatment on markers of mineral metabolism and routine laboratory variables. RESULTS: Twenty-seven subjects received placebo, and 25 received cholecalciferol. The majority (94%) of subjects had serum 25-hydroxyvitamin D [25(OH)D] concentrations <30 ng/mL. Study groups were similar with respect to baseline clinical characteristics, with the exception of hemoglobin concentrations, which were lower in the cholecalciferol-treated group (P < 0.04). At follow-up, 90.5% of subjects treated with cholecalciferol achieved serum 25(OH)D concentrations ≥30 ng/mL in contrast to 13.6% of the placebo group. There were no significant changes in serum calcium, phosphate, or intact parathyroid hormone during the study. CONCLUSION: Short-term, high-dose oral cholecalciferol treatment of vitamin D deficiency in hemodialysis patients appears to be effective and with no evidence of toxic effects. This trial was registered at clinicaltrials.gov as NCT00912782.
Authors: Daniel Zehnder; Martin J Landray; David C Wheeler; William Fraser; Lisa Blackwell; Sarah Nuttall; Sue V Hughes; John Townend; Charles Ferro; Colin Baigent; Martin Hewison Journal: Nephron Clin Pract Date: 2007-09-21
Authors: Prakash Chandra; José Nilo G Binongo; Thomas R Ziegler; Lynn E Schlanger; Wenli Wang; James T Someren; Vin Tangpricha Journal: Endocr Pract Date: 2008 Jan-Feb Impact factor: 3.443
Authors: M Wolf; A Shah; O Gutierrez; E Ankers; M Monroy; H Tamez; D Steele; Y Chang; C A Camargo; M Tonelli; R Thadhani Journal: Kidney Int Date: 2007-08-08 Impact factor: 10.612
Authors: Luigi Francesco Morrone; Pergiorgio Bolasco; Corrado Camerini; Giuseppe Cianciolo; Adamasco Cupisti; Andrea Galassi; Sandro Mazzaferro; Domenico Russo; Luigi Russo; Mario Cozzolino Journal: J Nephrol Date: 2016-04-09 Impact factor: 3.902
Authors: Dana C Miskulin; Karen Majchrzak; Hocine Tighiouart; Richard S Muther; Toros Kapoian; Doug S Johnson; Daniel E Weiner Journal: J Am Soc Nephrol Date: 2015-12-17 Impact factor: 10.121
Authors: Andrea Galassi; Antonio Bellasi; Sara Auricchio; Sergio Papagni; Mario Cozzolino Journal: Biomed Res Int Date: 2013-08-07 Impact factor: 3.411
Authors: Ruth E Grossmann; Susu M Zughaier; Meena Kumari; Shabnam Seydafkan; Robert H Lyles; Shuling Liu; Viranuj Sueblinvong; Michael S Schechter; Arlene A Stecenko; Thomas R Ziegler; Vin Tangpricha Journal: Dermatoendocrinol Date: 2012-04-01